港股异动 | 先声药业(02096)涨超9% 肿瘤领域创新药科赛拉近日获国家药监局批准常规上市
先声药业(02096)涨超9%，截至发稿，涨9.13%，报7.53港元，成交额9885.29万港元。
消息面上，先声药业近日发公告称，集团肿瘤领域创新药科赛拉®(注射用盐酸曲拉西利)已达成补充申请条件，获国家药品监督管理局(NMPA)批准由附条件上市转为常规上市，适应症为：适用于既往未接受过系统性化疗的广泛期小细胞肺癌患者(ES-SCLC)，在接受含铂类药物联合依托泊甘方案治疗前给药，以降低化疗引起的骨髓抑制的发生率。
据悉，科赛拉®是集团与G1 Therapeutics,INC.(G1)合作的细胞周期蛋白依赖性激酶CDK4/6抑制剂，是全球首个在化疗前给药，拥有全系骨髓保护作用的创新药物。
Reprinted from 引领外汇网，the copyright all reserved by the original author.
Disclaimer: The content above represents only the views of the author or guest. It does not represent any views or positions of FOLLOWME and does not mean that FOLLOWME agrees with its statement or description, nor does it constitute any investment advice. For all actions taken by visitors based on information provided by the FOLLOWME community, the community does not assume any form of liability unless otherwise expressly promised in writing.
FOLLOWME Trading Community Website: https://www.followme.com
Hot
No comment on record. Start new comment.